CLEMENT CHAN: Open Payments
NPI 1063601904 · ALHAMBRA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,197 in 50 payments from 12 companies in 2025. Trend: 2023 $156 · 2024 $433 · 2025 $1,197
Food & beverage: $1,197
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 13 | $383 |
| Novartis Pharmaceuticals Corporation | 9 | $212 |
| PFIZER INC. | 10 | $194 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $71 |
| Amgen Inc. | 3 | $67 |
| Kestra Medical Technology Services, Inc. | 3 | $66 |
| Actelion Pharmaceuticals US, Inc. | 3 | $44 |
| ABIOMED | 1 | $44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 1 | $36 |
Products named: VERQUVO, LEQVIO, ELIQUIS, VYNDAQEL, Kerendia, REPATHA, Assure WCD, UPTRAVI.
Industry payments across CA — which companies pay providers there.
